Delayed emesis: Moderately emetogenic chemotherapy

Fausto Roila, David Warr, Rebecca A. Clark-Snow, Maurizio Tonato, Richard J. Gralla, Lawrence H. Einhorn, Jorn Herrstedt

Research output: Contribution to journalReview article

62 Scopus citations

Abstract

Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT3 antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.

Original languageEnglish (US)
Pages (from-to)104-108
Number of pages5
JournalSupportive Care in Cancer
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2005

    Fingerprint

Keywords

  • 5-HT antagonist
  • Delayed emesis
  • Dexamethasone
  • Moderately emetogenic chemotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Roila, F., Warr, D., Clark-Snow, R. A., Tonato, M., Gralla, R. J., Einhorn, L. H., & Herrstedt, J. (2005). Delayed emesis: Moderately emetogenic chemotherapy. Supportive Care in Cancer, 13(2), 104-108. https://doi.org/10.1007/s00520-004-0700-8